Carcinogenesis, Vol. 20, No. 9, 1733-1736,
September 1999
© 1999 Oxford University Press
Molecular Epidemiology and Cancer Prevention |
Codon 72 polymorphism of p53 as a risk factor for patients with human papillomavirus-associated squamous intraepithelial lesions and invasive cancer of the uterine cervix
Department of Obstetrics and Gynecology, Asahikawa Medical College, Nishikagura 4-5-3-11, Asahikawa 078-8510, Japan
Squamous intraepithelial lesions (SIL) and invasive cancer of the uterine cervix are thought to be a series of lesions derived from normal cervical squamous tissue. Infection by high risk human papillomavirus (HPV) and integration of viral DNA may initially lead normal cervical cells to become pre-malignant cells in SIL and result in cervical malignancies later on. High risk HPVs, including types 16 and 18, produce a viral protein, E6, which is required for viral replication in host cells. The E6 protein is able to bind to host p53 causing inactivation of its function through the mechanism of ubiquitin-dependent degradation. It has recently been reported that the extent of p53 dysfunction caused by HPVs depends on the status of a polymorphism at codon 72 of p53, Pro or Arg. In that study, it was demonstrated that a patient homozygous for the Arg allele had about a seven times higher risk of developing cervical cancer than a patient homozygous for Pro. In an attempt to confirm this result and elucidate whether this allelic deviation of the Arg genotype seen in invasive cervical cancer occurs in the pre-malignant lesion SIL, we analyzed 219 SIL and 101 invasive cancer samples from Japanese patients using a PCR-based assay. Samples from 88 SIL and 76 invasive cancers were identified as HPV-infected samples and used for further analyses. In these, the frequencies of Arg homozygotes were 31.8, 33.0 and 36.8% in controls, SIL and invasive cancer, respectively. The distributions of the different alleles of codon 72 (Pro/Pro, Pro/Arg and Arg/Arg) did not show significant differences between either control and SIL groups or control and invasive cancer groups. Also, no difference in the frequency of Arg/Arg genotype was detected even between the control and HSIL groups or control and invasive cancer infected with high risk HPVs groups. In conclusion, there was no obvious relationship between the Arg genotype at codon 72 of p53 and predisposition to HPV-associated cervical neoplasia.
Abbreviations: HPV, human papillomavirus; SIL, squamous intraepithelial lesions.
1 Present address: Department of Cytology, Asahikawa Detection Center of Hokkaido Cancer Society, Suehiro-higashi 2-6, Asahikawa 071-8122, Japan
2 To whom correspondence should be addressed Email: tyamashi{at}asahikawa-med.ac.jp
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. Jain, V. Singh, S. Hedau, S. Kumar, M. K. Daga, R. Dewan, N. S. Murthy, S. A. Husain, and B. C. Das Infection of Human Papillomavirus Type 18 and p53 Codon 72 Polymorphism in Lung Cancer Patients From India Chest, December 1, 2005; 128(6): 3999 - 4007. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Koushik, R. W. Platt, and E. L. Franco p53 Codon 72 Polymorphism and Cervical Neoplasia: A Meta-Analysis Review Cancer Epidemiol. Biomarkers Prev., January 1, 2004; 13(1): 11 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A-M Martin, P A Kanetsky, B Amirimani, T A Colligon, G Athanasiadis, H A Shih, M R Gerrero, K Calzone, T R Rebbeck, and B L Weber Germline TP53 mutations in breast cancer families with multiple primary cancers: is TP53 a modifier of BRCA1? J. Med. Genet., April 1, 2003; 40(4): e34 - 34. [Full Text] [PDF]
|
|
|
|
 |
|
 E. S. Calhoun, R. M. McGovern, C. A. Janney, J. R. Cerhan, S. J. Iturria, D. I. Smith, B. S. Gostout, and D. H. Persing Host Genetic Polymorphism Analysis in Cervical Cancer Clin. Chem., August 1, 2002; 48(8): 1218 - 1224. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Berggren, R. Kumar, G. Steineck, M. Ichiba, and K. Hemminki Ethnic variation in genotype frequencies of a p53 intron 7 polymorphism Mutagenesis, November 1, 2001; 16(6): 475 - 478. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D P O'Connor, E W Kay, M Leader, G J Atkins, G M Murphy, and M J E M F Mabruk p53 codon 72 polymorphism and human papillomavirus associated skin cancer J. Clin. Pathol., July 1, 2001; 54(7): 539 - 542. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Tada, K. Furuuchi, M. Kaneda, J. Matsumoto, M. Takahashi, A. Hirai, Y. Mitsumoto, R. D Iggo, and T. Moriuchi Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants Carcinogenesis, March 1, 2001; 22(3): 515 - 517. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Berggren, K. Hemminki, and G. Steineck p53 intron 7 polymorphisms in urinary bladder cancer patients and controls Mutagenesis, January 1, 2000; 15(1): 57 - 60. [Abstract] [Full Text] [PDF]
|
|